SANUWAVE Health, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SANUWAVE Health, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.05M | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | $11.27M | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | $10.05M | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | $9.33M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $32.63M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $20.40M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $16.74M | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | $4.17M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $3.88M | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | $3.20M | Mar 31, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $32.33M | Mar 20, 2025 |
| FY2024 | Dec 31, 2023 | $19.26M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $15.51M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $11.38M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.63M | May 13, 2022 |
| FY2020 | Dec 31, 2019 | $1.03M | Oct 21, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.97M | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | $8.74M | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | $7.85M | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | $7.38M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $24.55M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $14.36M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $12.41M | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | $3.01M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $2.79M | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | $2.31M | Mar 31, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.81M | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | $9.69M | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | $551.0K | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | ($6.12M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($33.08M) | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | ($21.17M) | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | $6.19M | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | ($4.80M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($25.81M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($10.29M) | Mar 21, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.95M | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | $903.0K | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | $1.44M | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | $601.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.85M | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | $1.48M | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | $1.65M | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | ($1.29M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($540.0K) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($8.95M) | Mar 21, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.35M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $673.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $579.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $567.0K | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | $157.0K | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $171.0K | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | $166.0K | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $1.10M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.25M | May 13, 2022 |
| FY2020 | Dec 31, 2019 | $1.18M | Oct 21, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.88M | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | $557.0K | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | ($524.0K) | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | ($1.52M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.46M | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | $1.71M | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | $432.0K | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | $1.10M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($4.54M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($17.17M) | Mar 21, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.94M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $490.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 20, 2025 |
| FY2021 | Dec 31, 2021 | $529.0K | May 13, 2022 |
| FY2021 | Dec 31, 2020 | $53.0K | May 13, 2022 |
| FY2020 | Dec 31, 2019 | $53.9K | Oct 21, 2021 |
| FY2019 | Dec 31, 2018 | $42.9K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $10.4K | Mar 29, 2018 |
| FY2015 | Dec 31, 2014 | $8.9K | Mar 30, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.34M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $30.12M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $22.42M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $19.87M | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | $18.78M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $17.84M | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | $17.01M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $18.62M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $23.03M | May 13, 2022 |
| FY2020 | Dec 31, 2019 | $3.38M | Oct 21, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.72M | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | $43.19M | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | $51.85M | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | $51.67M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $45.91M | Mar 26, 2026 |
| FY2025 | Jan 1, 2024 | $66.96M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $65.59M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $60.88M | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | $54.09M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $53.38M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.62M | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | ($7.59M) | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | ($18.80M) | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | ($20.81M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($15.80M) | Mar 26, 2026 |
| FY2025 | Jan 1, 2024 | ($44.55M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | ($44.55M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | ($41.01M) | Mar 20, 2025 |
| FY2022 | Sep 30, 2022 | ($35.31M) | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | ($35.54M) | Mar 31, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.26M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.26M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $7.26M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $7.26M | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | $7.26M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $7.26M | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | $7.26M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $7.26M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $7.26M | May 13, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Oct 21, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($242.69M) | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | ($250.38M) | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | ($260.07M) | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | ($260.62M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($254.50M) | Mar 26, 2026 |
| FY2025 | Jan 1, 2024 | ($221.42M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($220.05M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($194.24M) | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | ($188.55M) | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | ($187.41M) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.96M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $10.24M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.80M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.15M | Mar 21, 2024 |
| FY2022 | Sep 30, 2022 | $1.11M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $1.48M | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | $313.0K | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $619.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.44M | May 13, 2022 |
| FY2020 | Dec 31, 2019 | $1.76M | Oct 21, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.89M | Mar 26, 2026 |
| FY2021 | Dec 31, 2021 | $26.26M | May 13, 2022 |
| FY2021 | Dec 31, 2020 | $16.74M | May 13, 2022 |
| FY2017 | Dec 31, 2016 | $5.37M | Mar 29, 2018 |
| FY2012 | Dec 31, 2012 | $5.37M | Mar 26, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | 1 | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (7) | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | (6) | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (12) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (7) | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | (6) | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (12) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.59M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 8.54M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 3.04M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 548.74M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 481.62M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 470.69M | May 13, 2022 |
| FY2020 | Dec 31, 2019 | 293.78M | Oct 21, 2021 |
| FY2019 | Dec 31, 2018 | 155.67M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 139.30M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 137.22M | Mar 29, 2018 |